This year, CBI is hosting the Thirteenth Annual Pharmaceutical Compliance Congress (PCC) January 26 – 27, 2016, at the Ritz Carlton in Washington, D.C.
This two-day event is packed with programming, including discussion of issues such as mergers and acquisitions, global transparency, off-label promotion, risk monitoring, cross-border compliance, and enforcement priorities.
Day One of the event starts with an opening address from Ashley Watson, Chief Ethics and Compliance officer at Merck & Co, Inc., who will be speaking about how to unite compliance and the business, to raise the bar and reinforce global collaboration. Following that is a showcase, where attendees will hear from leading Chief Compliance Officers on a variety of the most pressing issues impacting today’s business world. CCOs who will be on that showcase panel include: Trudy Tan, AstraZeneca; Jill Fallows-Macaluso, Novo Nordisk Inc.; and John Crisan, Johnson & Johnson. Later that morning, attendees will also hear from a selection of USAO on healthcare fraud enforcement trends and future compliance issues, and former prosecutors of high-profile healthcare fraud cases.
A Chief Compliance Officer Summit will take place the afternoon of January 26, where Chief Compliance Officers will be permitted to discuss common questions, challenges, and issues that are facing CCOs today. For those attendees who are not CCOs, many opportunities await them, including a choice of six varied workshops, covering a wide variety of material, including government pricing updates, pre-M&A due diligence, and the unique risks associated with specialty drugs. Following the workshops, attendees will have their choice of four different tracks of speakers, including tracks focused on product promotional compliance and compliance considerations for clinical research and R&D. At the close of day one, a wine and cheese reception is held for networking purposes.
Day Two opens with an update from the FBI, presented by Jeffrey S. Salley, Special Agent in Charge, followed by an address by Robin Usi, Director of the Division of Data and Informatics at CMS. Day Two continues with an option of five different tracks, ranging in topics from global and international compliance strategies to off-label risks and controls. Day Two ends with four working group discussion options, including one discussion on the 21st Century Cures Act and its impact on compliance, where attendees will engage in small group conversation with peers, sharing first hand experience and asking constructive questions to spark dialogue.
The PCC sees over 400 attendees annually in a variety of backgrounds, with 74% of attendees being from the bio/pharma/device community.
Additionally, this year, CBI is hosting a “PCC Prelude” the afternoon of January 25, 2016. There are two events that make up the PCC Prelude, both from 3:00pm – 5:00pm and invitation-only, the Emerging Leaders’ Summit and the Advanced Think Tank Summit for Small Mid-Sized Life Sciences Companies.
If you are interested in attending the Thirteenth Annual Pharmaceutical Compliance Congress, you can register here. As an added bonus, Policy & Medicine readers are offered a $400* registration discount by entering the code PCCPM4 with their registration.
* This discount applies to standard rate and may not be combined with other offers or applied to an existing registration.